Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria (HCU)
December 14, 2023 07:30 ET | Travere Therapeutics, Inc.
SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the Company has opened enrollment in the HARMONY Study, a global, randomized pivotal Phase 3...
BMUSIC.PNG
BMUSIC is an AI compose music automatically according to the user requests
February 18, 2023 17:30 ET | BMUSIC
SINGAPORE , Feb. 18, 2023 (GLOBE NEWSWIRE) -- The speculation surrounding the potential impact of artificial intelligence (AI) on the music industry has come to an end. AI technology has already...
ITM_Logo_Claim_RGB_high-res.png
ITM to Present Trial Design of Ongoing Phase III COMPOSE Study in Advanced Neuroendocrine Tumors at ESMO 2022
September 06, 2022 05:00 ET | ITM Isotope Technologies Munich SE
Garching / Munich, September 6, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that a scientific poster on the design of its second...